Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe

• Published in: Future oncology (London, England) p. 1
• Main Authors: Diez-Campelo, Maria, Yucel, Aylin, Goyal, Ravi K, Parikh, Rohan C, Esterberg, Elizabeth, Jimenez, Maria, Sluga-O'Callaghan, Martina, Miteva, Dimana, Xiao, Hong, Germing, Ulrich
• Format: Journal Article
• Language: English
• Published: England 14.08.2024
• Subjects: lower-risk myelodysplastic syndromes; hematologic outcomes; real-world data; non-del(5q); treatment patterns
• ISSN: 1744-8301
• DOI: 10.1080/14796694.2024.2379228

To assess treatment patterns and outcomes in patients with non-del(5q) lower-risk myelodysplastic syndromes. Patient medical records were reviewed in the USA, Canada (CAN), UK and the EU. Analysis included 119 patients in the USA/CAN (median age, 61.5 years) and 245 patients in the UK/EU (median age, 67.3 years). Most patients received erythropoiesis-stimulating agents (ESAs) as first-line (1L) therapy (USA/CAN: 89.0%; UK/EU: 90.2%). A substantial proportion of 1L erythropoiesis-stimulating agent-treated patients were transfusion dependent before 1L (USA/CAN: 37.1%; UK/EU: 51.2%); a small percentage of these patients achieved transfusion independence during 1L therapy (USA/CAN: 2.8%; UK/EU: 14.4%). These findings highlight an unmet need for more effective treatments among patients with non-del(5q) lower-risk myelodysplastic syndromes.